Figure 6.
FAF-Rapa outperforms other carriers in suppressing tumors when injected SC. Athymic nude mice (n = 6-8 per group) with orthotopic 30-180 mm3 MDA-MB-468 tumors were treated three times a week SC with (a) PBS (b) Free Rapa (c) FAF-Rapa (d) FA-Rapa and (e) FSI-Rapa at 0.75 mg/kg dose. (f) Tumor burden (Equation S4) by day 50 (mean ± SD) was statistically significant for the comparisons between PBS and Free Rapa, FAF-Rapa each (Tukey's post-hoc analysis, α = 0.05, *p = 0.03, ○p = 0.03 respectively). (g) Kaplan-Meier analysis shows Free Rapa and FAF-Rapa also had longer survival end points than the PBS treated control (Log-rank post-hoc analysis, α = 0.0125, p = 0.003 and 0.003 respectively). (h) There were no long-term trends in body weight (mean ± SD), except for the free Rapa group which recovered after a mild decrease in the first week of treatment.